Core protein inhibitors: Opportunities and challenges at the forefront of hepatitis B cure: Editorial on "Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients"
- PMID: 38741237
- PMCID: PMC11540340
- DOI: 10.3350/cmh.2024.0346
Core protein inhibitors: Opportunities and challenges at the forefront of hepatitis B cure: Editorial on "Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients"
Keywords: Antiviral therapy; Core portein inhibitor; Functional cure; Hepatitis B virus.
Conflict of interest statement
The authors have no conflicts to disclose.
Comment on
-
Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients.Clin Mol Hepatol. 2024 Jul;30(3):375-387. doi: 10.3350/cmh.2023.0535. Epub 2024 Mar 26. Clin Mol Hepatol. 2024. PMID: 38528825 Free PMC article. Clinical Trial.
References
-
- Wang J, Shen T, Huang X, Kumar GR, Chen X, Zeng Z, et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound. J Hepatol. 2016;65:700–710. - PubMed
Publication types
LinkOut - more resources
Full Text Sources